Impact of Del Nido Versus Blood Cardioplegia on Myocardial Viability Assessed With Magnetic Resonance Imaging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorKlinički Bolnički Centar Zagreb
About this trial
Myocardial protection during surgical myocardial revascularization is crucial for reducing perioperative myocardial injury and improving postoperative outcomes. Blood cardioplegia represents the standard method in many centers, while del Nido cardioplegia, originally developed for the pediatric population, is increasingly being used in adult patients as well.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Left ventricular ejection fraction <30%
Associated cardiac procedures
Off-pump coronary artery bypass grafting
Contraindications for MRI
Trial design
Design model
Parallel
Treatments tested in this trial
Del Nido Cardioplegia Solution for myocardial protection
DrugCABG patients receiving Del Nido cardioplegia as the myocardial protection strategy
Blood Cardioplegia Solution for myocardial protection
DrugPatients will receive Blood Cardioplegia Solution for myocardial protection
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Del Nido cardioplegiaActive comparator 1 intervention
Group B: Blood cardioplegiaActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Myocardial Viability Assessed by Magnetic Resonance Imaging
Myocardial Viability Assessed by Magnetic Resonance Imaging
Time frame
Patients will undergo the initial cardiac MRI scan before surgery. The follow-up MRI will be scheduled approximately 4 weeks after surgical revascularization.Secondary outcomes
1
Major Adverse Cardiac and Cerebrovascular Events
The secondary outcome will be a composite of mortality, periprocedural myocardial infarction, stroke, and cardiac rehospitalization
Time frame
MACCE will be adjudicated at 30 days and 6 months.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov